{"id":"https://openalex.org/W2604494474","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3051","title":"ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study","display_name":"ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2604494474","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3051","mag":"2604494474"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.3051","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3051","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.3051","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048380048","display_name":"John Victor Heymach","orcid":"https://orcid.org/0000-0001-9068-8942","observed_orcids":["https://orcid.org/0000-0001-9068-8942"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. V. Heymach","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210117453","https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060490490","display_name":"Runyu Dong","orcid":"https://orcid.org/0009-0006-0576-436X","observed_orcids":["https://orcid.org/0009-0006-0576-436X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R.-P. Dong","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210117453","https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007514323","display_name":"Isaiah W. Dimery","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. Dimery","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210117453","https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112819256","display_name":"Cathy Wheeler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Wheeler","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210117453","https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109543691","display_name":"Panagiotis M. Fidias","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Fidias","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210117453","https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040318340","display_name":"C. Lu","orcid":"https://orcid.org/0000-0002-5786-9431","observed_orcids":["https://orcid.org/0000-0002-5786-9431"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Lu","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210117453","https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053521833","display_name":"Bruce Evan Johnson","orcid":"https://orcid.org/0000-0002-5252-3677","observed_orcids":["https://orcid.org/0000-0002-5252-3677"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Johnson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210117453","https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5008593691","display_name":"Roy S. Herbst","orcid":"https://orcid.org/0000-0003-2535-5847","observed_orcids":["https://orcid.org/0000-0003-2535-5847"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Herbst","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA; AstraZeneca, Wilmington, DE; University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210117453","https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"3051","last_page":"3051"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9643999934196472,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9643999934196472,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.021800000220537186,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.005200000014156103,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vandetanib","display_name":"vandetanib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9900000095367432},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9929999709129333},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8489999771118164},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.6679999828338623},{"id":"https://openalex.org/keywords/run-in-phase","display_name":"run-in phase","score":0.6320000290870667}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9291181564331055},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8604439496994019},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6389312148094177},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5708507895469666},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.537154495716095},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.4802558720111847},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.46483466029167175},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4350472092628479},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4348493814468384},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.4263342022895813},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3735102415084839},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.366854190826416},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3255324959754944}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.3051","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.3051","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.3051","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.3051","doi":"https://doi.org/10.1200/jco.2004.22.90140.3051","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.3051","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2285987216","https://openalex.org/W2537283502","https://openalex.org/W1991655476","https://openalex.org/W2230520814","https://openalex.org/W2249043129","https://openalex.org/W7218113500","https://openalex.org/W7064026820","https://openalex.org/W2051383707","https://openalex.org/W2029615277","https://openalex.org/W2294386671"],"abstract_inverted_index":{"3051":[0],"Background:":[1],"ZD6474":[2,35,96,114,159,257,286,300,311],"is":[3,314,344],"a":[4,126,147,197,216],"novel,":[5],"orally":[6],"available":[7],"VEGFR-2":[8],"TKI":[9],"that":[10,256,307],"also":[11,229],"has":[12,305],"activity":[13],"against":[14],"EGFR.":[15],"Objective":[16],"tumor":[17],"responses":[18],"in":[19,164,186,200,320],"NSCLC":[20,59],"patients":[21],"(pts)":[22],"were":[23,50],"observed":[24,269],"during":[25],"Phase":[26,31],"I":[27],"evaluation.":[28],"In":[29,80],"this":[30,121],"II":[32],"trial":[33],"of":[34,47,62,69,120,129,149,152,188,296,310],"plus":[36,95],"docetaxel":[37],"(doc),":[38],"the":[39,48,81,110,136,176,273,283,308,326,337],"safety,":[40],"efficacy,":[41],"and":[42,73,156,208,226,312,325],"possible":[43],"pharmacokinetic":[44],"(PK)":[45],"interaction":[46],"combination":[49,138,309,343],"assessed.":[51],"Methods:":[52],"Eligibility":[53],"included":[54],"locally":[55],"advanced":[56],"or":[57,71,77,132,194,234,242,340,349,352],"metastatic":[58],"after":[60],"failure":[61],"1st":[63],"line":[64],"platinum-based":[65],"chemotherapy,":[66],"WHO":[67,127],"status":[68,128],"0":[70,130],"1,":[72],"no":[74,103],"significant":[75,318],"hematologic":[76],"cardiac":[78],"abnormalities.":[79],"open-label":[82],"Part":[83],"1":[84,133,233],"phase,":[85,122],"pts":[86,124,165,237],"received":[87,113,135,146],"doc":[88,153,250,277,313],"(75":[89],"mg/m2":[90],"every":[91],"21":[92],"days,":[93],"i.v.)":[94],"(100":[97,139,339],"mg":[98,140,143],"once":[99],"daily,":[100],"p.o.).":[101],"If":[102],"dose-limiting":[104],"toxicity":[105],"occurred":[106],"by":[107,211,215],"week":[108],"4,":[109],"next":[111],"cohort":[112],"300":[115,142,341],"mg.":[116],"Results:":[117],"At":[118],"completion":[119],"15":[123],"with":[125,196,266,291,293,299,317,336],"(N=6)":[131],"(N=9)":[134],"ZD6474/doc":[137,170],"N=4,":[141],"N=11).":[144],"Pts":[145],"median":[148],"4":[150,243],"cycles":[151,174],"(range":[154,160],"1\u201311)":[155],"12":[157],"weeks'":[158],"2\u201329).":[161],"Preliminary":[162,252],"evaluation":[163],"who":[166],"continued":[167],"to":[168,180,246,249,261,264,272,285,322],"receive":[169],"for":[171,276],"\u2265":[172],"3":[173,185,241],"revealed":[175],"most":[177],"common":[178],"AE":[179],"be":[181,247],"rash":[182,205],"(CTC":[183,231],"grade":[184,232],"6":[187],"9":[189],"pts),":[190],"classified":[191],"as":[192,222],"acneiform":[193],"desquamation,":[195],"photosensitivity":[198],"component":[199],"all":[201],"affected":[202],"patients.":[203],"The":[204,330],"was":[206,209,287],"reversible,":[207],"manageable":[210],"dose":[212,217],"interruption":[213],"followed":[214],"reduction.":[218],"Other":[219,361],"AEs":[220],"such":[221],"GI":[223],"complaints":[224],"(nausea/vomiting)":[225],"laboratory":[227],"abnormalities":[228],"occurred,":[230],"2).":[235],"Seven":[236],"experienced":[238],"CTC":[239],"Grade":[240],"myelosuppression":[244],"thought":[245],"related":[248],"treatment.":[251],"PK":[253],"assessment":[254],"shows":[255],"did":[258],"not":[259,315],"appear":[260],"affect":[262],"exposure":[263,284,321],"doc,":[265,292],"any":[267],"changes":[268,295,319],"being":[270],"similar":[271],"intra-patient":[274],"variability":[275],"alone.":[278,301],"No":[279],"marked":[280],"effect":[281],"on":[282],"seen":[288],"when":[289],"administered":[290],"maximal":[294],"\u00b120%":[297],"compared":[298],"Conclusions:":[302],"This":[303],"phase":[304,333],"confirmed":[306],"associated":[316],"either":[323],"drug":[324],"toxicities":[327],"are":[328],"manageable.":[329],"double-blind,":[331],"randomized":[332],"comparing":[334],"doc/placebo":[335],"doc/ZD6474":[338],"mg)":[342],"ongoing.":[345],"Author":[346],"Disclosure":[347],"Employment":[348],"Leadership":[350],"Consultant":[351],"Advisory":[353],"Stock":[354],"Ownership":[355],"Honoraria":[356],"Research":[357],"Funding":[358],"Expert":[359],"Testimony":[360],"Remuneration":[362],"AstraZeneca":[363,364,365]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-04-14T00:00:00"}